MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has advanced the CimetrA™ anti-inflammatory treatment a step closer to clinical trials with the completion of an in-vitro pre-clinical mechanism of action (MoA) study.
The GLP-Certified Science in Action Lab in Ness Ziona, Israel, carried out the study, which examined the underlying mechanism of the CimetrA-mediated anti-inflammatory effect on human Peripheral Blood Mononuclear Cells (PBMC).
The study demonstrated CimetrA’s inhibitory effect on mRNA expression and thus secretion of IL-32 proteins, which subsequently suppressed inflammation and inflammatory cytokines (immune system-signalling proteins).
Large anti-inflammatory target market
“The completion of this study has advanced our understanding of the biological mechanisms and demonstrated CimetrA’s effective in the treatment of inflammatory disease," MGC Pharmaceuticals co-founder and managing director Roby Zomer said.
This "will allow us to open the target market not only as COVID-19 treatment but to the whole anti-inflammatory treatments, such keeping the relevancy of CimetrA™ as more than just seasonal hype treatment but as long-term treatment offering.
“The data from this study provides critical confirmation in the pathway to drug development and means that we can further target the specific biological functions in our formulation.”
Additional findings from the study demonstrated that CimetrA also increases intracellular HO-1, the antioxidant activity in cells, protecting against oxidative stress that causes the inflammation.
The study results will form part of the US Food and Drug Administration (FDA) application to register CimetrA™ as an Investigational New Drug (IND).